Allogeneic donor-derived CD19 CAR-T therapy of relapsed B-cell acute lmphoblastic leukemia after allogeneic hematopoietic stem cell transplantation

• Published in: Zhōnghuá xuèyèxué zázhì Vol. 42; no. 5; p. 383
• Main Authors: Ma, R Z, He, Y, Yang, D L, Wei, J L, Pang, A M, Jiang, E L, Wang, J X, Han, M Z, Zhang, R L, Feng, S Z
• Format: Journal Article
• Language: Chinese
• Published: China 14-05-2021
• Subjects: Antigens, CD19; B-Lymphocytes; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy, Adoptive; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Receptors, Chimeric Antigen; Relapse; Allogeneic hematopoietic stem cell transplantation; CAR-T cell; CD19; B cell acute lymphoblastic leukemia
• ISSN: 0253-2727
• DOI: 10.3760/cma.j.issn.0253-2727.2021.05.006

To investigate the long term efficacy and side effects of a donor-derived CD19 chimeric antigen receptor (CAR) T-cell (HI19α-4-1BB-ζ CAR-T) therapy in the treatment of patients with relapsed B-cell acute lymphoblastic leukemia (B-ALL) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) .
A total of 9 subjects with relapsed B-ALL post allo-HSCT received donor-derived CD19 CAR-T therapy from July 2017 to May 2020. All subjects were infused with donor CD3-positive T cells after lymphodepletion chemotherapy, and a median dose of CAR-T cells was 1.79 (range, 0.86-3.53) ×10(6)/kg.
①All subjects achieved complete remission and MRD-negative at 28-42 d post CAR-T cells infusion. ②Cytokine releasing syndrome (CRS) occurrd in all subjects and was grade 3 in 2, grade 2 in 4, grade 1 in 3 cases respectively. Four subjects developed immune effector cell-associated neurotoxicity syndrome (ICANS) , which was grade 2 in 1, grade 1 in 3. One subject developed grade IV acute graft-versus-host disease (GVHD) , a